decernotinib   Click here for help

GtoPdb Ligand ID: 8309

Synonyms: adelatinib | VRT-831509 | VX-509
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Decernotinib is a selective inhibitor of Janus kinase 3 (JAK3) [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 95.59
Molecular weight 392.16
XLogP 3.27
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCC(C(=O)NCC(F)(F)F)(Nc1ccnc(n1)c1c[nH]c2c1cccn2)C
Isomeric SMILES CC[C@](C(=O)NCC(F)(F)F)(Nc1ccnc(n1)c1c[nH]c2c1cccn2)C
InChI InChI=1S/C18H19F3N6O/c1-3-17(2,16(28)25-10-18(19,20)21)27-13-6-8-23-15(26-13)12-9-24-14-11(12)5-4-7-22-14/h4-9H,3,10H2,1-2H3,(H,22,24)(H,25,28)(H,23,26,27)/t17-/m1/s1
No information available.
Summary of Clinical Use Click here for help
Decernotinib reached Phase 3 clinical trial as a potential treatment for rheumatoid arthritis (RA), but development appears to have been terminated, apparently for strategic reasons.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Inhibition of JAK3 mediates signalling via a small subset of cytokine receptors, with which JAK3 (and JAK1) associate. These include the receptors for IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 which share a common γ receptor chain. Partial or reversible inhibition of JAK3 provides effective modulation of the immune activity in conditions such as autoimmune disorders.